201 related articles for article (PubMed ID: 31560833)
1. Increased cytoplasmatic expression of cancer immune surveillance receptor CD1d in anaplastic thyroid carcinomas.
Weber F; Junger H; Werner JM; Velez Char N; Rejas C; Schlitt HJ; Hornung M
Cancer Med; 2019 Nov; 8(16):7065-7073. PubMed ID: 31560833
[TBL] [Abstract][Full Text] [Related]
2. [Immunohistochemical studies of mononuclear cellular infiltrates of papillary, follicular and anaplastic thyroid cancers].
Kornfehl J; Wilfing A; Hermann M
Laryngorhinootologie; 1994 Apr; 73(4):183-8. PubMed ID: 8011021
[TBL] [Abstract][Full Text] [Related]
3. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
4. [Cytokeratin expression of benign and malignant epithelial thyroid gland tumors. An immunohistologic study of 154 neoplasms using 8 different monoclonal cytokeratin antibodies].
Schröder S; Wodzynski A; Padberg B
Pathologe; 1996 Nov; 17(6):425-32. PubMed ID: 9082363
[TBL] [Abstract][Full Text] [Related]
5. A study of FoxA1 expression in thyroid tumors.
Nonaka D
Hum Pathol; 2017 Jul; 65():217-224. PubMed ID: 28546130
[TBL] [Abstract][Full Text] [Related]
6. CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors.
Min IM; Shevlin E; Vedvyas Y; Zaman M; Wyrwas B; Scognamiglio T; Moore MD; Wang W; Park S; Park S; Panjwani S; Gray KD; Tassler AB; Zarnegar R; Fahey TJ; Jin MM
Clin Cancer Res; 2017 Dec; 23(24):7569-7583. PubMed ID: 29025766
[No Abstract] [Full Text] [Related]
7. PAX8 immunostaining of anaplastic thyroid carcinoma: a reliable means of discerning thyroid origin for undifferentiated tumors of the head and neck.
Bishop JA; Sharma R; Westra WH
Hum Pathol; 2011 Dec; 42(12):1873-7. PubMed ID: 21663937
[TBL] [Abstract][Full Text] [Related]
8. Detection of HLA-DR antigens in paraffin-embedded thyroid epithelial cells with a monoclonal antibody.
Lloyd RV; Johnson TL; Blaivas M; Sisson JC; Wilson BS
Am J Pathol; 1985 Jul; 120(1):106-11. PubMed ID: 3893150
[TBL] [Abstract][Full Text] [Related]
9. Expression of intermediate filament proteins in thyroid gland and thyroid tumors.
Miettinen M; Franssila K; Lehto VP; Paasivuo R; Virtanen I
Lab Invest; 1984 Mar; 50(3):262-70. PubMed ID: 6199582
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive screening for PD-L1 expression in thyroid cancer.
Ahn S; Kim TH; Kim SW; Ki CS; Jang HW; Kim JS; Kim JH; Choe JH; Shin JH; Hahn SY; Oh YL; Chung JH
Endocr Relat Cancer; 2017 Feb; 24(2):97-106. PubMed ID: 28093480
[TBL] [Abstract][Full Text] [Related]
11. Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target.
Magro G; Cataldo I; Amico P; Torrisi A; Vecchio GM; Parenti R; Asioli S; Recupero D; D'Agata V; Mucignat MT; Perris R
Thyroid; 2011 Mar; 21(3):267-77. PubMed ID: 21323588
[TBL] [Abstract][Full Text] [Related]
12. Iodine deficiency and thyroid nodular pathology--epidemiological and cancer characteristics in different populations: Portugal and South Africa.
Santos JE; Kalk WJ; Freitas M; Marques Carreira I; Castelo Branco M
BMC Res Notes; 2015 Jul; 8():284. PubMed ID: 26126625
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of a hobnail pattern in papillary, poorly differentiated, and anaplastic thyroid carcinoma: a possible manifestation of high-grade transformation.
Amacher AM; Goyal B; Lewis JS; El-Mofty SK; Chernock RD
Am J Surg Pathol; 2015 Feb; 39(2):260-5. PubMed ID: 25321328
[TBL] [Abstract][Full Text] [Related]
14. Polysialic acid of the neural cell adhesion molecule in the human thyroid: a marker for medullary thyroid carcinoma and primary C-cell hyperplasia. An immunohistochemical study on 79 thyroid lesions.
Komminoth P; Roth J; Saremaslani P; Matias-Guiu X; Wolfe HJ; Heitz PU
Am J Surg Pathol; 1994 Apr; 18(4):399-411. PubMed ID: 8141431
[TBL] [Abstract][Full Text] [Related]
15. Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer.
Bastman JJ; Serracino HS; Zhu Y; Koenig MR; Mateescu V; Sams SB; Davies KD; Raeburn CD; McIntyre RC; Haugen BR; French JD
J Clin Endocrinol Metab; 2016 Jul; 101(7):2863-73. PubMed ID: 27045886
[TBL] [Abstract][Full Text] [Related]
16. Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-Like.
Giannini R; Moretti S; Ugolini C; Macerola E; Menicali E; Nucci N; Morelli S; Colella R; Mandarano M; Sidoni A; Panfili M; Basolo F; Puxeddu E
J Clin Endocrinol Metab; 2019 Aug; 104(8):3557-3575. PubMed ID: 30882858
[TBL] [Abstract][Full Text] [Related]
17. Expression of inducible nitric oxide synthase in thyroid neoplasms: immunohistochemical and molecular analysis.
Choe W; Kim S; Hwang TS; Lee SS
Pathol Int; 2003 Jul; 53(7):434-9. PubMed ID: 12828608
[TBL] [Abstract][Full Text] [Related]
18. CA 50 and CA 19-9 antigen expression in normal, hyperplastic, and neoplastic thyroid tissue.
Vierbuchen M; Schröder S; Uhlenbruck G; Ortmann M; Fischer R
Lab Invest; 1989 May; 60(5):726-32. PubMed ID: 2716285
[TBL] [Abstract][Full Text] [Related]
19. SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas.
Moraitis D; Karanikou M; Liakou C; Dimas K; Tzimas G; Tseleni-Balafouta S; Patsouris E; Rassidakis GZ; Kouvaraki MA
Surgery; 2014 Dec; 156(6):1542-8; discussion 1548-9. PubMed ID: 25456951
[TBL] [Abstract][Full Text] [Related]
20. Three-dimensional structure of the micro-blood vessels in thyroid tumors analyzed by immunohistochemistry coupled with image analysis.
Hama Y; Suzuki K; Shingu K; Fujimori M; Kobayashi S; Usuda N; Amano J
Thyroid; 1999 Sep; 9(9):927-32. PubMed ID: 10524572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
